Multisocietal European consensus on the terminology, diagnosis, and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE.
Journal
The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553
Informations de publication
Date de publication:
11 08 2023
11 08 2023
Historique:
received:
12
03
2023
accepted:
13
04
2023
medline:
14
8
2023
pubmed:
14
7
2023
entrez:
13
7
2023
Statut:
ppublish
Résumé
Contemporary management of patients with synchronous colorectal cancer and liver metastases is complex. The aim of this project was to provide a practical framework for care of patients with synchronous colorectal cancer and liver metastases, with a focus on terminology, diagnosis, and management. This project was a multiorganizational, multidisciplinary consensus. The consensus group produced statements which focused on terminology, diagnosis, and management. Statements were refined during an online Delphi process, and those with 70 per cent agreement or above were reviewed at a final meeting. Iterations of the report were shared by electronic mail to arrive at a final agreed document comprising 12 key statements. Synchronous liver metastases are those detected at the time of presentation of the primary tumour. The term 'early metachronous metastases' applies to those absent at presentation but detected within 12 months of diagnosis of the primary tumour, the term 'late metachronous metastases' applies to those detected after 12 months. 'Disappearing metastases' applies to lesions that are no longer detectable on MRI after systemic chemotherapy. Guidance was provided on the recommended composition of tumour boards, and clinical assessment in emergency and elective settings. The consensus focused on treatment pathways, including systemic chemotherapy, synchronous surgery, and the staged approach with either colorectal or liver-directed surgery as first step. Management of pulmonary metastases and the role of minimally invasive surgery was discussed. The recommendations of this contemporary consensus provide information of practical value to clinicians managing patients with synchronous colorectal cancer and liver metastases.
Sections du résumé
BACKGROUND
Contemporary management of patients with synchronous colorectal cancer and liver metastases is complex. The aim of this project was to provide a practical framework for care of patients with synchronous colorectal cancer and liver metastases, with a focus on terminology, diagnosis, and management.
METHODS
This project was a multiorganizational, multidisciplinary consensus. The consensus group produced statements which focused on terminology, diagnosis, and management. Statements were refined during an online Delphi process, and those with 70 per cent agreement or above were reviewed at a final meeting. Iterations of the report were shared by electronic mail to arrive at a final agreed document comprising 12 key statements.
RESULTS
Synchronous liver metastases are those detected at the time of presentation of the primary tumour. The term 'early metachronous metastases' applies to those absent at presentation but detected within 12 months of diagnosis of the primary tumour, the term 'late metachronous metastases' applies to those detected after 12 months. 'Disappearing metastases' applies to lesions that are no longer detectable on MRI after systemic chemotherapy. Guidance was provided on the recommended composition of tumour boards, and clinical assessment in emergency and elective settings. The consensus focused on treatment pathways, including systemic chemotherapy, synchronous surgery, and the staged approach with either colorectal or liver-directed surgery as first step. Management of pulmonary metastases and the role of minimally invasive surgery was discussed.
CONCLUSION
The recommendations of this contemporary consensus provide information of practical value to clinicians managing patients with synchronous colorectal cancer and liver metastases.
Identifiants
pubmed: 37442562
pii: 7223848
doi: 10.1093/bjs/znad124
pmc: PMC10416695
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1161-1170Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd and published by Elsevier Ltd on behalf of the International Hepato-Pancreato-Biliary Association Inc.
Références
Br J Surg. 2012 Sep;99(9):1263-9
pubmed: 22864887
Br J Surg. 2012 Aug;99(8):1097-104
pubmed: 22696424
Nat Commun. 2018 May 4;9(1):1793
pubmed: 29728604
Eur J Surg Oncol. 2022 Aug;48(8):1815-1822
pubmed: 35461740
World J Surg Oncol. 2019 Dec 26;17(1):228
pubmed: 31878952
JAMA Surg. 2013 Apr;148(4):385-91
pubmed: 23715907
Lancet Gastroenterol Hepatol. 2021 Nov;6(11):933-946
pubmed: 34506756
BMC Cancer. 2018 Aug 15;18(1):821
pubmed: 30111304
Ann Surg. 2023 Sep 1;278(3):e540-e548
pubmed: 36453261
J Surg Oncol. 2015 May;111(6):716-24
pubmed: 25864987
Lancet. 2018 Jun 23;391(10139):2537-2545
pubmed: 29976470
JAMA. 2014 May 14;311(18):1863-9
pubmed: 24825641
BMC Cancer. 2020 Sep 7;20(1):862
pubmed: 32894078
Clin Transl Oncol. 2019 Jan;21(1):46-54
pubmed: 30565083
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Cancer Treat Rev. 2015 Nov;41(9):729-41
pubmed: 26417845
Am J Surg. 2022 Jul;224(1 Pt A):217-227
pubmed: 35000753
Lancet Gastroenterol Hepatol. 2017 Sep;2(9):627
pubmed: 28786383
Ann Surg Oncol. 2022 Mar;29(3):1939-1951
pubmed: 34716838
BMC Cancer. 2021 Oct 23;21(1):1139
pubmed: 34688256
J Visc Surg. 2011 Jun;148(3):e171-82
pubmed: 21703959
World J Surg. 2023 Jan;47(1):11-34
pubmed: 36310325
Clin Colorectal Cancer. 2022 Mar;21(1):63-70
pubmed: 34852972
Ann Surg Oncol. 2022 Dec;29(13):8385-8393
pubmed: 35974233
Eur J Cancer. 2017 Jun;78:7-15
pubmed: 28407529
HPB (Oxford). 2019 Nov;21(11):1446-1452
pubmed: 30956165
Eur J Cancer. 2018 Sep;100:35-45
pubmed: 29936065
Crit Rev Oncol Hematol. 2023 Mar;183:103927
pubmed: 36706968
Nat Rev Clin Oncol. 2014 Aug;11(8):446-59
pubmed: 24889770
Healthcare (Basel). 2022 Sep 28;10(10):
pubmed: 36292345
World J Surg. 2022 Dec;46(12):3081-3089
pubmed: 36209339
Minerva Surg. 2022 Dec;77(6):582-590
pubmed: 36409039
Ecancermedicalscience. 2022 Dec 15;16:1489
pubmed: 36819812
Plast Reconstr Surg. 2011 Jul;128(1):305-310
pubmed: 21701348
Hepatobiliary Pancreat Dis Int. 2016 Oct;15(5):458-460
pubmed: 27733314
HPB (Oxford). 2015 Nov;17(11):983-7
pubmed: 26252426
World J Surg. 2018 Dec;42(12):4046-4053
pubmed: 29947991
Radiol Clin North Am. 2022 Sep;60(5):679-694
pubmed: 35989037
Endoscopy. 2021 Aug;53(8):850-868
pubmed: 34062566
Ann Oncol. 2023 Jan;34(1):10-32
pubmed: 36307056
Ann Surg. 2018 Jul;268(1):11-18
pubmed: 29064908
J Clin Oncol. 2023 Jan 20;41(3):678-700
pubmed: 36252154
Front Oncol. 2022 Jul 12;12:916455
pubmed: 35903708
Ann Surg. 2021 Jan 1;273(1):49-56
pubmed: 32209911
Ann Surg Oncol. 2021 Dec;28(13):8198-8208
pubmed: 34212254
Cancers (Basel). 2023 Feb 10;15(4):
pubmed: 36831497
Colorectal Dis. 2022 May;24(5):601-610
pubmed: 35142008
J Gastrointest Oncol. 2022 Aug;13(4):2033-2047
pubmed: 36092339
Anticancer Res. 2022 Dec;42(12):6099-6103
pubmed: 36456125
HPB (Oxford). 2023 Jan;25(1):26-36
pubmed: 36167765
Ann Surg. 2021 Jul 1;274(1):1-3
pubmed: 33630445
Front Immunol. 2022 Dec 23;13:1019582
pubmed: 36618386
JAMA Surg. 2021 Dec 1;156(12):1093-1101
pubmed: 34613339
World J Gastrointest Oncol. 2021 Dec 15;13(12):1850-1862
pubmed: 35070029
Cancers (Basel). 2022 Sep 05;14(17):
pubmed: 36077874
Br J Surg. 2022 Mar 15;109(4):303-305
pubmed: 35134831
World J Gastroenterol. 2015 Jun 14;21(22):7014-21
pubmed: 26078580
J Clin Oncol. 2021 Apr 1;39(10):1098-1107
pubmed: 33560877
Int J Colorectal Dis. 2020 Mar;35(3):537-546
pubmed: 31955217